Thus, CTLA-4 and IDO blockade combination significantly decreased tumor volume by 50% after 80 days, while during CTLA-4 blockade and imatinib administration alone tumors expanded by 40–60% over a similar period (117). This evidence concerns the gene IDO1 and neoplasm.